Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 17 Issue 1, January 2021

Inspired by the Review on p17

Cover design: S.Harris.

Research Highlights

Top of page ⤴

News & Views

  • The ability to predict how a patient might respond to a medication would shift treatment decisions away from trial and error and reduce disease-associated health and financial burdens. Machine learning approaches applied to genomic datasets offer great promise to deliver personalized medicine but their application must first be optimized.

    • Darren Plant
    • Anne Barton
    News & Views
  • The new 2019 EULAR–ACR classification criteria for systemic lupus erythematosus (SLE) performed well in the initial derivative and validation cohorts. But do these criteria outperform previous classification criteria across sexes, disease durations or ethnicities?

    • Guillermo J. Pons-Estel
    • Graciela S. Alarcón
    News & Views
  • For young people with rheumatic diseases, the transition from paediatric to adult rheumatology care is a vulnerable time, and delays or disruption in their care can lead to adverse outcomes. Research into the factors associated with gaps in transitional care could improve the identification and targeting of vulnerable groups.

    • Kirsten Minden
    News & Views
Top of page ⤴


Top of page ⤴


  • Nerve growth factor has been investigated as a therapeutic target for osteoarthritis and chronic low back pain, yet worries over adverse effects have stalled drug development. This Review provides an update on the current status of nerve growth factor inhibitors.

    • Barton L. Wise
    • Matthias F. Seidel
    • Nancy E. Lane
    Review Article
  • The development of osteoarthritis (OA) correlates with an increase in the number of senescent cells in joint tissues and the senescence-associated secretory phenotype is implicated in cartilage degradation and OA. Eliminating or altering senescent cells with senolytics or senomorphics could stop OA progression and pathogenesis.

    • Philip R. Coryell
    • Brian O. Diekman
    • Richard F. Loeser
    Review Article
Top of page ⤴


Top of page ⤴


Quick links